| Drug Name |
Tetrofosmin |
| Drug ID |
BADD_D02190 |
| Description |
Tetrofosmin was developed to overcome the non-target uptake of radioligands by the generation of hetero-atomic compounds. It presents a molecular formula of 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane. Tetrofosmin is part of the group of diphosphines. Tetrofosmin is used in conjunction with technetium Tc-99m as a radiopharmaceutical.[A7788] |
| Indications and Usage |
Tetrofosmin is indicated to be used as a complex with technetium Tc-99m for scintigraphic imaging of the myocardium following separate administrations under exercise and/or resting conditions. It helps in the delineation of regions of reversible myocardial ischemia in absence of infarcted myocardium.[L2001]
This complex is also used for scintigraphic imaging of the myocardium to identify changes in perfusion induced by pharmacologic stress in patients with known or suspected coronary artery disease.[L2001]
This complex is indicated for the assessment of left ventricular function in patients evaluated for heart disease.[L2001] |
| Marketing Status |
approved |
| ATC Code |
Not Available |
| DrugBank ID |
DB11180
|
| KEGG ID |
D06094
|
| MeSH ID |
C078700
|
| PubChem ID |
4274
|
| TTD Drug ID |
D05HFN
|
| NDC Product Code |
17156-024; 17156-026; 71806-026 |
| UNII |
3J0KPB596Q
|
| Synonyms |
technetium tc-99m tetrofosmin | technetium-99m-tetrofosmin | technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane | 99mTc-tetrafosmin | 99mTc-tetrofosmin | Tc-99m-tetrofosmin | technetium(1+)-99tc, bis(6,9-bis(2-ethoxyethyl)-3,12-dioxa-6,9-diphosphatetradecane-.kappa.p,.kappa.p')dioxo-, (oc-6-11)- | Myoview | PPN-1011 | Tc-99m-PPN1011 | PPN1011 |
